SNTI
Senti Biosciences Holdings, Inc. (SNTI) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C (2.4) | C- (2.0) | F (0.4) | F (0.6) | C+ (2.6) | D+ (1.6) |
| 2026-11-08 | C (2.3) | C- (2.0) | F (0.4) | D- (0.8) | C+ (2.6) | D+ (1.6) |
| 2026-11-01 | C (2.3) | C- (1.9) | F (0.4) | D- (0.8) | C+ (2.7) | D+ (1.6) |
| 2026-10-25 | C (2.3) | C- (1.9) | F (0.4) | D- (0.8) | C+ (2.6) | D+ (1.6) |
| 2026-10-18 | C (2.3) | C- (1.9) | F (0.4) | D- (0.8) | C+ (2.6) | D+ (1.6) |